News

Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?
J&J has an Earnings ESP of +2.40% and a Zacks Rank #2 (Buy), indicating a likely positive surprise. Per our proven model, ...
Kenvue's CEO Search and SHB Review Raise Questions, but Core Brands Still Show Stability
Kenvue has five brands that generate over $1 billion in sales—Johnson’s, Neutrogena, Listerine, Tylenol, and Aveeno—as well as a number of brands that generate over $400 million in sales: Nicorette, ...
Zacks Investment Research on MSN3d
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
Johnson & Johnson’s JNJ second-quarter 2025 earnings came in at $2.77 per share, which beat the Zacks Consensus Estimate of $2.66. Earnings, however, declined 1.8% from the year-ago period. Adjusted ...
J&J Talc Creditor Firms Decry Judge’s Failure to Address Fees
A Houston bankruptcy judge who dismissed the Chapter 11 case for Johnson & Johnson’s talc liability unit improperly refused ...
‘Dirty Little Secret’: Another J&J Talc Trial Opens in Boston
Dallas-based Dean Omar Branham Shirley is handling another talcum powder trial against Johnson & Johnson, which began on ...
Johnson & Johnson: The Worst Is Baked In
J&J's diversified business, robust pipeline, and strong free cash flow provide stability, despite legal challenges. Read more ...
J&J doesn't have to 'do deals out of desperation' despite facing patent cliffs: CFO
Johnson & Johnson (JNJ) reported stronger-than-expected second quarter earnings Wednesday, beating Wall Street expectations on both the top and bottom lines. The company reported $23.7 billion in ...